124485-41-2
Chemical Structure
Z-Val-Val-Arg-AMC
- CAS No.: 124485-41-2
- Formula:C34H45N7O7
- Molecular Weight:663.76
IUPAC Name: benzyl ((S)-1-(((S)-1-(((S)-5-guanidino-1-((4-methyl-2-oxo-2H-chromen-7-yl)amino)-1-oxopentan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate
InChIKey: VCOVUYXJMHMVNV-FMYROPPKSA-N
SMILES: CC(C1=CC=C(NC([C@@H](NC([C@@H](NC([C@@H](NC(OCC2=CC=CC=C2)=O)C(C)C)=O)C(C)C)=O)CCCNC(N)=N)=O)C=C1O3)=CC3=O
Biological Activity: Z-Val-Val-Arg-AMC is a fluorescent peptide substrate that can be used to test the activity of cathepsins. Z-Val-Val-Arg-AMC exhibits preference for Cathepsin S. Z-Val-Val-Arg-AMC undergoes hydrolysis catalyzed by cathepsin to release the AMC fluorophore, thereby enabling fluorescence-based quantitative assessment of the target enzyme activity[1][2][3][4][5][6][7][8].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Z-Val-Val-Arg-AMC | 99.44% | Z-Val-Val-Arg-AMC is a fluorescent peptide substrate that can be used to test the activity of cathepsins. Z-Val-Val-Arg-AMC exhibits preference for Cathepsin S. Z-Val-Val-Arg-AMC undergoes hydrolysis catalyzed by cathepsin to release the AMC fluorophore, thereby enabling fluorescence-based quantitative assessment of the target enzyme activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Schmid H, et al. Specific catalytic activity of cathepsin S in comparison to cathepsins B and L along the rat nephron. Biological chemistry. 1997 Feb;378(2):61-9.
- [2]. Baugh M, et al. Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity. Journal of autoimmunity. 2011 May;36(3-4):201-9. [Content Brief]
- [3]. Creasy BM, et al. New assay using fluorogenic substrates and immunofluorescence staining to measure cysteine cathepsin activity in live cell subpopulations. Cytometry. Part A : the journal of the International Society for Analytical Cytology. 2007 Feb;71(2):114-23.
- [4]. Kubo K, et al. Effective suppression of donor specific antibody production by Cathepsin S inhibitors in a mouse transplantation model. European journal of pharmacology. 2018 Nov 05;838:145-152.
- [5]. Clark AK, et al. Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain. Proceedings of the National Academy of Sciences of the United States of America. 2007 Jun 19;104(25):10655-60. [Content Brief]
- [6]. Na BK, et al. Identification and biochemical characterization of vivapains, cysteine proteases of the malaria parasite Plasmodium vivax. The Biochemical journal. 2004 Mar 01;378(Pt 2):529-38.
- [7]. Figueiredo JL, et al. Selective cathepsin S inhibition attenuates atherosclerosis in apolipoprotein E–deficient mice with chronic renal disease. The American journal of pathology. 2015 Apr 1;185(4):1156-66.
- [8]. Kenniston JA, et al. Inhibition of plasma kallikrein by a highly specific active site blocking antibody. The Journal of biological chemistry. 2014 Aug 22;289(34):23596-608. [Content Brief]
